The niche under siege: novel targets for metastasis therapy

Authors

  • A. Santamaria-Martínez,

    1. École Polytechnique Fédérale de Lausanne (EPFL), ISREC (Swiss Institute for Experimental Cancer Research), National Center of Competence in Research (NCCR) ‘Molecular Oncology’, Lausanne, Switzerland
    Search for more papers by this author
  • J. Huelsken

    Corresponding author
    • École Polytechnique Fédérale de Lausanne (EPFL), ISREC (Swiss Institute for Experimental Cancer Research), National Center of Competence in Research (NCCR) ‘Molecular Oncology’, Lausanne, Switzerland
    Search for more papers by this author

Correspondence: J. Huelsken, Ecole Polytechnique Fédérale de Lausanne (EPFL), ISREC (Swiss Institute for Experimental Cancer Research) and National Center of Competence in Research (NCCR) ‘Molecular Oncology’, Lausanne, Switzerland.

(fax: +41 (0) 21 693 07 70; e-mail ID: joerg.huelsken@epfl.ch).

Abstract

Metastasis is an inefficient process and most cancer cells fail to colonize secondary sites. There are several possible reasons for this. First, the nature of the infiltrating cells is important as a small population of cancer stem cells has been shown to have exclusive metastasis-initiating potential. Secondly, supportive niches are required to promote the outgrowth of disseminated tumour cells. Such niches are either produced prior to the arrival of cancer cells in the target organ or are induced ad hoc upon cell infiltration. Components of the extracellular matrix (ECM) have been found to play a role in establishing these niches. This has highlighted the importance of the ECM for metastatic progression, and suggests that such components may provide alternative targets for treatment of metastatic disease.

Ancillary